How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,054 results for

Pruritus in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Treatment of Uremic Pruritus With PA101B

active treatment with a systemic drug Participation in any other investigation drug study within 4 weeks of Screening Current or anticipated use of baclofen, gabapentin, pregabalin and nalbuphine for the treatment of pruritus Current or anticipated use of glucocorticoids administered intravenously, orally, or transdermally Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study Contacts and Locations Go (...) Treatment of Uremic Pruritus With PA101B Treatment of Uremic Pruritus With PA101B - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Uremic Pruritus With PA101B The safety and scientific validity

2016 Clinical Trials

62. Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Volunteers: No Criteria Inclusion Criteria: Male and non-pregnant, non-lactating female subjects aged 18 - 65 years (inclusive); Diagnosed with atopic dermatitis Suffering from chronic pruritus with pruritus being actively present Exclusion Criteria: Chronic pruritus due to condition other than atopic dermatitis (AD) Participation in a previous tradipitant (LY686017 or VLY-686) trial; Anyone affiliated with the site or sponsor and/or anyone who may consent under duress; Any other sound medical reason (...) Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2016 Clinical Trials

63. Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

or continue washout of medication and return for Day -7 Visit procedures after washout. At Baseline Period 1 Day 0: NRS for Pruritus score of at least 5 recorded in the subject diary on at least 4 of the 7 days preceding Baseline Period 1 Day 0. Pruritic treatment area of 5-95% of the subject's total treatable body surface area. Subject can be expected to reliably follow treatment instructions and visit schedule. Non-pregnant, non-lactating females of childbearing potential who agree to use medically (...) Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2016 Clinical Trials

64. Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

a negative serum pregnancy test and agree to practice an acceptable form of birth control for the duration of the study Male patients that are not biologically or surgically sterile must agree to practice an acceptable from of birth control for the duration of the study Weigh between 88.2 lb (40.0 kg) and 297.6 lb (135.0 kg). Patient must self-report pruritus in the month prior to screening. If patient is receiving treatment for itch, this treatment must be stable prior to screening and during treatment (...) Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2016 Clinical Trials

65. Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.

Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging. Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging. (PRURIM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02828787 Recruitment Status : Recruiting First Posted : July 12, 2016 Last

2016 Clinical Trials

66. Itch in pregnancy

in 5 pregnant women. Obstetric cholestasis is the main cause of itch without a rash in pregnancy. The itch (often severe) usually starts abruptly in the third trimester on the soles of the feet and palms of the hands, and spreads to become more generalized. It is often worse at night. Obstetric cholestasis generally poses no risk to the pregnant woman. Although it is associated with an increased risk of stillbirth, this appears to be only slightly raised above background rates with specialist (...) NICE quality standards No NICE quality standards were found during the review of this topic. Background information Background information Definition What is it? Itch (also known as pruritus) is described as an unpleasant sensation that triggers a desire to scratch [ ]. Causes of itch What causes it? Itch in pregnancy may be caused by: A pre-existing or coincidental condition — see the CKS topic on for more information. A condition that is specific to pregnancy. The most common

2015 NICE Clinical Knowledge Summaries

67. Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Age>20y/o, ESRD patient, pruritus symptoms persist longer than 4 weeks Exclusion Criteria: immunosupression agents use, undergo chemotherapy drug abuser pregnancy women patient with psychiological disorder arrhythemia, pacemaker device use local skin infection over laser acupuncture site patient allergy to laser acupuncture treament Contacts and Locations Go to Information (...) Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2015 Clinical Trials

68. Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02475447 Recruitment Status : Completed First Posted : June 18, 2015 Last

2015 Clinical Trials

69. A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus

by such allergic material as scabies, and insect bite wound Patients with the symptom of systemic infection at the time of the participation in the clinical study Patients with a history of taking topical treatment drug, topical steroid agent or antibiotics for the treatment of pruritus within 2 weeks Patients with a history of taking oral steroid agent within 4 weeks Patients with a history of taking a physical treatment for the treatment of pruritus including phototherapy within 4 weeks Pregnant or breast (...) A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2015 Clinical Trials

70. Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

pruritus (VAS score ≥ 4) first occur after EGFR TKIs treatment Life expectancy ≥ 3 months Orally drug administration with no difficulty pregnancy test negative in 7 days for women of child-bearing age; willing to take contraception measures. Signed informed consent form (ICF) Exclusion Criteria: Systemically treatment with Neurokinin-1 (NK-1) receptor inhibitors, antihistamines drugs, antibiotics, cortical hormone therapy, antiepileptic drugs, immunosuppressive agents or other drugs might affect (...) Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Aprepitant vs

2015 Clinical Trials

71. Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02373215 Recruitment Status : Completed First Posted : February 26, 2015 Last Update Posted : February 26, 2015 Sponsor: Trevi Therapeutics

2015 Clinical Trials

72. Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (PSORITUS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02362789 Recruitment Status : Completed First Posted : February 13, 2015 Results First Posted : December 28, 2018 Last Update Posted : December 28

2015 Clinical Trials

73. IBAT Inhibitor A4250 for Cholestatic Pruritus

IBAT Inhibitor A4250 for Cholestatic Pruritus IBAT Inhibitor A4250 for Cholestatic Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. IBAT Inhibitor A4250 for Cholestatic Pruritus The safety (...) of this study is to assess the safety and tolerability of A4250, 1.5 - 3 mg orally during a four-week treatment period, in patients with PBC and cholestatic pruritus, as determined by the occurrence of treatment-emergent serious adverse events (SAEs). Other safety objectives of this study include assessment of the safety and tolerability of A4250 during a four-week treatment period, as determined by the occurrence of treatment-emergent adverse events (AEs) and changes in other safety parameters including

2015 Clinical Trials

74. Prevalence, antimicrobial resistance and serotype distribution of group B streptococcus isolated among pregnant women and newborns in Rabat, Morocco. Full Text available with Trip Pro

recruited. The prevalence of pregnant women colonized by GBS was 24 %. In 5/160 additional sick newborns recruited with suspected sepsis, the blood cultures were positive for GBS. Gestational hypertension and vaginal pruritus were significantly associated with a vagino-rectal GBS colonization in univariate analyses. All of the strains were susceptible to penicillin, while 7 % were resistant to clindamycin and 12 % were resistant to erythromycin. The most common GBS serotypes detected included V, II (...) Prevalence, antimicrobial resistance and serotype distribution of group B streptococcus isolated among pregnant women and newborns in Rabat, Morocco. Group B streptococcus (GBS) is an important cause of neonatal sepsis worldwide. Data on the prevalence of maternal GBS colonization, risk factors for carriage, antibiotic susceptibility and circulating serotypes are necessary to tailor adequate locally relevant public health policies.A prospective study including pregnant women and their newborns

2018 Journal of Medical Microbiology

75. Pruritus

Pruritus Pruritus (PDQ®)—Health Professional Version - National Cancer Institute Menu Search Search Search Overview Pruritus is usually an unpleasant sensation that elicits a desire to scratch, subjectively quantified by intensity, severity, location, and intractability. It may be proposed that itch is akin to pain, as both are thought to be transmitted from skin to central nervous system (CNS) through nociceptive small-caliber C nerve fibers.[ ] Perception of pruritus, much like pain (...) , is greatly altered by psychological and CNS factors, thereby accounting for the great subjective variability between individuals in perceived pruritus from the same pruritogen. Because of the subjective nature of pruritus, the lack of a precise definition, and the lack of suitable animal models, pruritus is a disorder that has not been researched adequately. For the purpose of this discussion, a focus will be placed on pruritus in the absence of a primary dermatosis, as is often encountered in patients

2012 PDQ - NCI's Comprehensive Cancer Database

76. Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Full Text available with Trip Pro

Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Asymptomatic bacteriuria occurs in 5% to 10% of pregnancies and, if left untreated, can lead to serious complications.To assess which antibiotic is most effective and least harmful as initial treatment for asymptomatic bacteriuria in pregnancy.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (March 2010) and reference lists of retrieved studies.Randomized controlled trials comparing two (...) (risk ratio (RR) 1.36, 95% confidence interval (CI) 0.24 to 7.75), shift to other antibiotics (RR 0.08, 95% CI 0.00 to 1.45), or in allergy or pruritus (RR 2.73, 95% CI 0.11 to 65.24). A comparison of seven-day courses of 400 mg pivmecillinam versus 500 mg ampicillin, both given four times daily, showed no significant difference in persistent infection at two weeks or recurrent infection, but there was an increase in vomiting (RR 4.57, 95% CI 1.40 to 14.90) and women were more likely to stop

2010 Cochrane

77. Pregnancy detecting plants used in Remo and Ijebu areas of Ogun State, Nigeria Full Text available with Trip Pro

had the UV of 0.08, respectively. B. diffusa L, C. kolly (Schumach) Hepper tested positive for the presence of flavonoids, alkaloids, and tannins. The onset and duration of symptoms of both B. diffusa and C. kolly leaves at 2000 and 1000 mg were dose-dependent. The hexane, ethyl acetate, and ethanol extracts of B. diffusa and C. kolly exhibited pruritus and restlessness in the in vivo model while the urine of pregnant women caused black spots on the leaves of L. taraxacifolia (Willd) Amin Ex. C (...) Pregnancy detecting plants used in Remo and Ijebu areas of Ogun State, Nigeria Plants and plants extracts are employed in cultures for religious purposes, as beauty therapies, in the detection and management/treatment of diseases.In this study, an ethnobotanical studies of plants used in detecting pregnancy in Ijebu and Remo areas of Ogun State were carried out using semi-structured to obtain demographic data, local names of plants, the morphological parts used. Furthermore, a phytochemical

2016 Journal of intercultural ethnopharmacology

78. Intrahepatic Cholestasis of Pregnancy with Severe Elevation of Bile Acids in the Setting of Acute Hepatitis C Infection Full Text available with Trip Pro

Intrahepatic Cholestasis of Pregnancy with Severe Elevation of Bile Acids in the Setting of Acute Hepatitis C Infection Intrahepatic cholestasis of pregnancy (ICP) is a complication of pregnancy resulting in elevation of serum bile acid levels. ICP is often associated with underlying liver disease, including hepatitis C. Bile acids in relationship to the acute infection of hepatitis C virus have not yet been delineated in the literature. A 26-year-old gravida 4 para 2103 with dichorionic (...) , diamniotic twin gestation and history of intravenous drug abuse developed ICP in the setting of acute hepatitis C infection. In addition to clinical symptoms of pruritus and right upper quadrant pain, she developed severe elevation in bile acids, 239 micromol/L, and transaminitis aspartate aminotransferase 1033 U/L, and alanine aminotransferase 448 U/L. She received ursodeoxycholic acid and antenatal testing was performed. Patient delivered vaginally at 33-week gestation following preterm rupture

2016 Case reports in obstetrics and gynecology

79. A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy Full Text available with Trip Pro

A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy Intrahepatic cholestasis of pregnancy (ICP) is a common liver disorder, mostly occurring in the third trimester. ICP is defined as an elevation of serum bile acids, typically accompanied by pruritus and elevated activities of liver aminotransferases. ICP is caused by impaired biliary lipid secretion, in which endogenous steroids may play a key role. Although ICP is benign for the pregnant woman

2016 PloS one

80. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. (Abstract)

Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. Intrahepatic cholestasis of pregnancy (ICP) is a special complication of pregnancy characterized by skin pruritus, abnormal liver function tests and bile acids. To compare the efficacy of ursodeoxycholic acid (UDCA) and S-adenosylmethionine (SAMe) monotherapy with their combined effect on intrahepatic cholestasis of pregnancy (ICP).Singleton (...) pregnancies with ICP in five tertiary medical centers were randomly divided into three treatment groups: oral UDCA 4×250 mg daily (Group 1, n = 41), intravenous SAMe 1000 mg daily (Group 2, n = 38), and a combination of both drugs (Group 3, n = 41) until delivery. Paired t test, analysis of covariance and non-parametric test were used.All therapies significantly and equally improved pruritus. The serum levels of total bile acids (TBA), alanine aminotransferase (ALT), aspartate aminotransferase (AST

2015 European review for medical and pharmacological sciences Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>